Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Rating of “Moderate Buy” by Analysts

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $7.25.

Several analysts recently weighed in on MIST shares. Raymond James Financial started coverage on shares of Milestone Pharmaceuticals in a report on Friday, April 10th. They issued a “strong-buy” rating and a $6.00 price target on the stock. Zacks Research cut shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Friday, May 15th. Wall Street Zen cut shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th. Finally, Wells Fargo & Company cut their price target on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Thursday, May 14th.

Milestone Pharmaceuticals Stock Up 0.3%

Shares of Milestone Pharmaceuticals stock opened at $1.30 on Friday. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.09 and a current ratio of 9.18. Milestone Pharmaceuticals has a 52-week low of $1.00 and a 52-week high of $3.06. The stock has a market capitalization of $162.35 million, a price-to-earnings ratio of -1.92 and a beta of 0.95. The company’s 50 day moving average price is $1.63 and its 200-day moving average price is $1.80.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.26). The company had revenue of $0.24 million for the quarter, compared to analyst estimates of $30.12 million. Equities research analysts forecast that Milestone Pharmaceuticals will post -0.97 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Joseph Oliveto sold 36,500 shares of Milestone Pharmaceuticals stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $2.26, for a total value of $82,490.00. Following the sale, the chief executive officer owned 446,244 shares in the company, valued at $1,008,511.44. The trade was a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.03% of the stock is currently owned by company insiders.

Institutional Trading of Milestone Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Propel Bio Management LLC lifted its position in Milestone Pharmaceuticals by 186.1% during the third quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock valued at $10,250,000 after buying an additional 3,333,333 shares during the period. Orbimed Advisors LLC purchased a new position in Milestone Pharmaceuticals during the third quarter valued at $6,444,000. Marshall Wace LLP lifted its position in Milestone Pharmaceuticals by 289.8% during the fourth quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock valued at $3,347,000 after buying an additional 1,231,793 shares during the period. Pathstone Holdings LLC purchased a new position in Milestone Pharmaceuticals during the third quarter valued at $2,000,000. Finally, Boxer Capital Management LLC purchased a new position in Milestone Pharmaceuticals during the third quarter valued at $1,333,000. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.